key: cord-0829673-xtyo25of
authors: Bharat, Ankit; Hoetzenecker, Konrad
title: Lung transplantation for acute respiratory distress syndrome
date: 2022-01-31
journal: Thorac Surg Clin
DOI: 10.1016/j.thorsurg.2022.01.005
sha: 0c1288d6c411d9e8fa766a9c1b3c5f80c576717f
doc_id: 829673
cord_uid: xtyo25of

In this review, we discuss the outcomes of patients with severe acute respiratory distress syndrome. We discuss evidence which suggests that a significant proportion of patients with ARDS develop end-stage lung disease and die of pulmonary complications. In carefully selected patients with permanent lung damage, lung transplant can be a life-saving treatment.

The World Health Organization reports that respiratory illnesses are one of the top 5 causes of global deaths ). For example, influenza alone causes 40-60 million new infections each year in the United States alone with 40-60,000 deaths; a large majority due to the development of lung injury and the acute respiratory distress syndrome (ARDS). Both infectious and noninfectious etiologies cause ARDS. While global population-based estimate of the incidence of ARDS are mere approximations, it can vary from about 3.65 to 86.0 cases per 100,000 personyears. 1, 2 The incidence in the United States is one of the highest, ranging from 64.2 to 86.0 cases/100,000 person-years or about 200,000 cases annually. 3 It is estimated that about 10 to 15% of patients admitted to the intensive care unit (ICU) and up to 23% of mechanically ventilated patients meet the definition of ARDS. [4] [5] [6] [7] In an international study of nearly 30,000 ICU patients, 10% of admissions to the ICU were due to ARDS. 8 Accordingly to the Berlin definition, ARDS is classified as mild, moderate, or severe, based on the ratio of arterial partial pressure of oxygen (Pa O2 ) and fraction of inspired oxygen (FI O2 ) of 300, 200, and 100 mm. 9 Only about 25% of ARDS cases are initially classified as mild while 75% are moderate to severe. A third of the mild cases go on to progress to moderate or severe disease. The mortality associated with mild, moderate, and severe disease is 27%, 32%, and 45%, respectively, with a pooled mortality of about 43%. 10, 11 Hence, the burden of disease from ARDS is tremendous.

ARDS represents a common terminal pathway of lung injury that spans highly variable phases in response to a variety of etiologies. It starts with alveolar-capillary damage leading to a proliferative phase, usually associated with lung healing and improvement in pulmonary function, and ultimately resulting in a fibrotic phase, which marks the end of the acute injury.

The key histologic changes include alveolar edema, endothelial and epithelial injury, and leakage of proteinaceous fluid and blood into the alveolar space. Patients with ARDS are J o u r n a l P r e -p r o o f susceptible to nosocomial infections, multiorgan dysfunction, and baro-or volu-trauma, which along with their underlying health status and comorbidities can influence the outcomes, which range from spontaneous recovery to severe lung parenchymal necrosis, bronchiectasis, or fibroproliferation. With advances in ICU care, the mortality in patients with severe ARDS has decreased but still remains substantial. 12 Death early in the course of severe ARDS is related to complications such as pneumonia, sepsis and multiorgan dysfunction. However, in those who survive the early infectious complications, development of fibroproliferation can predispose to nosocomial complications with inability to wean the mechanical life support, ultimately leading to redirection of care to comfort measures in a large proportion of patients. 13 Studies indicate that substantial fibroproliferation resulting in insufficient pulmonary function is common in patients with ARDS. [14] [15] [16] Evidence of extensive collagen deposition has been described as early as the first 72 hours following the onset of ARDS 17, 18 and presence of collagen products, such as procollagen peptide III, correlate with fatal outcomes. 19 The release of profibrotic chemicals such as TGF-β1 and insulin-like growth factor-I have been shown to be released and proposed to contribute to the fibroproliferative response in patients with ARDS. 20 Clinically evident fibroproliferation is common even with the low tidal volume ventilation. 21 Pulmonary fibrosis is characterized by aberrant and disorganized collagen deposition in the lung parenchyma, particularly affecting the alveolar spaces, similar to that observed in some chronic end-stage lung diseases.

We recently compared the three-dimensional matrix organization of normal human lungs with those obtained from either patients with severe COVID-19 ARDS or those with end-stage idiopathic pulmonary fibrosis necessitating transplantation. While normal human lungs showed a well-formed intricate matrix, those obtained from COVID-19 ARDS showed complete absence of matrix organization with punctate islands of cells surrounding fibrotic airway regions. This pattern was similar to that observed in lungs from patients with end-stage idiopathic pulmonary fibrosis. 22, 23 Transcriptional atlases created using single cell RNA-Sequencing (RNA-Seq) [24] [25] [26] [27] have identified unique cell populations in the fibrotic lung that could J o u r n a l P r e -p r o o f be causally implicated in the development of fibrosis. [28] [29] [30] [31] Using a transfer learning approach 32 to compare single cell RNA-Seq data from lung tissue of patients with end-stage pulmonary fibrosis 26 and COVID-19 ARDS, we found striking homology between the two across many cell populations. We additionally found that a population of cells, expressing TP63, KRT5, KRT17, LAMB3, LAMC2, VIM, CHD2, FN1, COL1A1, TNC, HMGA2 and several senescence markers (CDKN1A, CDKN2A, CCND1, CCND2, MDM2, SERPINE1), accumulate during fibrosis, potentially contributing to disease pathogenesis through expression of TGFB1, ITGAV and ITGB6. 26, 27 In the normal lung, expression of KRT17 is restricted to basal, club, and ciliated cells in the proximal airways but they are absent in distal airways. 24, 26 In contrast to the normal lungs, these cells were readily observed in patients with end-stage COVID-19 and pulmonary fibrosis in distal airways. Furthermore, direct comparison of differential gene expression in KRT17+ cells between patients with pulmonary fibrosis and COVID-19 did not identify genes uniquely present in one condition, further highlighting similarities between these conditions. Additionally, comparison of differential gene expression in macrophages between patients with pulmonary fibrosis and COVID-19 ARDS also demonstrated considerable similarities between these two conditions. Our analysis also identified small group of cells observed in COVID-19 ARDS patients characterized by either expression of genes involved in calcium (AK5, SIGLEC15, CKB and SLC9B2), iron (SLC40A1, CD163) and lipid (MERTK, PLTP, ABCA1) metabolism, as well as motility and immune signaling (MARCKS, TLR2, CCL20), likely reflecting superinfection and ongoing inflammation in patients with ARDS. 22, 23 Profibrotic macrophages stimulate fibroblasts by forming self-sustaining circuits promoted by autogenous release of growth factors. 33, 34 Our data indicated that fibroblasts from patients with pulmonary fibrosis and those from patients with severe COVID-19 were largely similar. Collectively, these data suggest that some patients with COVID-19 ARDS develop end-stage lung disease, which is similar to other conditions such as pulmonary fibrosis.

Unfortunately, no medical or pharmacological therapies targeting fibroproliferation have been effective. Steroids have also failed to show improvement in outcomes in patients with ARDS associated fibroproliferation. 35 Other agents such as tyrosine kinase inhibitors. 36 

The medical debate about the use of lung transplantation for patients with ARDS is centered around the topics of "benefit" and "candidacy". Concerns include the potential for recurrence of the inciting infections in the allograft, technical challenges imposed by the acute injury to the native lung, and potential risk for allograft infection by pathogens associated with ventilatorassociated pneumonia in the native lung. More importantly, the native lung might recover, resulting in long-term outcomes preferable to transplant. We believe that the following two broad criteria could be considered to determine the need for transplantation in patients with ARDS. First, the lung damage is sufficient to prevent weaning from the mechanical life support, both the mechanical ventilator and/or extracorporeal membrane oxygenation (ECMO) support, after sufficient time from the onset of ARDS has elapsed and optimized medical treatment has been administered. Second, there is a development of pulmonary or pleural complications which are refractory to medical treatment. Some common scenarios associated with these criteria include the development of fibroproliferative ARDS, lung necrosis with cavitation or pneumatoceles, or severe bronchiectasis. How to accurately identify patients who would not recover spontaneously and benefit from lung transplantation remains unclear. The preferred approach in our experience has been to continue to provide medical management in patients as long as lung recovery is deemed possible since patients have been reported to spontaneously recover after extended duration of extracorporeal life support (ECLS). 22 

While post-transplant outcomes for chronic lung diseases are established, the benefit of lung transplantation for ARDS is still emerging. 40 Patients with severe ARDS are critically ill and develop considerable ICU-related comorbidities by the time lung recovery is deemed unlikely and transplant is considered. The medical course of severe ARDS is also often complicated by pulmonary complications such as pneumothorax, hemothorax, empyema, lung necrosis, and nosocomial pneumonias. 41 Hence, there are concerns related to the technical feasibility of lung transplantation in these patients, potentially inferior post-transplant outcomes due to frailty, and recurrence of nosocomial pathogens following transplantation. Besides a handful of case reports, three larger case series on lung transplantation for ARDS have been published to date ( Table 1 ). The first series reported the experience of this practice in a cohort of Korean patients. A total of 14 patients were evaluated and 9 ultimately received a transplantation between 2008 and 2013. 40 Importantly, three of the transplants were in fact combined heartlung transplantation due to left ventricular failure, right-sided heart insufficiency or severe were the predominant causes of ARDS. 43 The UNOS database study could not provide detailed data on ARDS cause.

There is general agreement that lung transplantation for ARDS is complex and the intra-and postoperative management is challenging. Thus, an outcome similar to other indications (ILD, CF, COPD) may not be expected. In fact, the data from the three above mentioned cohort studies confirmed this assumption. All three series report prolonged mechanical ventilation after lung transplantation with a median length of mechanical ventilation (LMV) of 11-33 days 40, 43 and a prolonged hospital stay with a median of 33-56 days (Table 1) . 40, 42, 43 However, these results are comparable to other complex patient groups, especially those with acute on chronic lung disease who require ECLS bridging to lung transplant. [44] [45] [46] [47] [48] Long-term survival following lung transplantation for ARDS was also lower compared to contemporary benchmarks. The Korean group reported 1-and 3-year survival rates of 78%. One patient out of nine (11.1%) died in the immediate postoperative course. 40 resulting in an in-hospital mortality rate of 7.7%. Survival rates were 71.6% at one year and 54.2% at five years. As these studies included patients going back as far as 1993, the possibility of an era effect on outcomes should be considered, especially as the European group reported improved outcomes for ARDS patients transplanted after 2016. 43 Nevertheless, patients bridged with ECMO to transplant reach comparable survival rates of 76-88% at 1 year, 61-83% at 3 years and 55-68% at 5 years. [44] [45] [46] [47] [48] [49] [50] Indeed, our recent study from an international cohort of COVID-19 ARDS patients supports that lung transplantation may be a viable lifesaving treatment option for severe COVID-19 associated ARDS even those being supported on ECMO. Collectively, currently available evidence leads to the conclusion that carefully selected ARDS patients can achieve lung transplantation outcomes comparable to other patients in similarly severe condition.

It is self-evident that in the acute setting of an ARDS, some routine examinations performed to determine lung transplant candidacy have to be waived. For instance, since the vast majority of ARDS patients who are considered for transplantation are young, the likelihood of an undetected malignancy or a significant cardiovascular comorbidity is low. We suggest the following examinations are important: Bridging patients awake has become an increasingly used practice in lung transplantation. In some centers, an awake patient is even considered a prerequisite for transplantation. In our opinion, there are mainly two reasons for this: 1) several studies have shown that the outcome of patients who can be bridged awake is significantly better compared to patients who are bridged sedated to . 45, 51, 52 2) The decision for a lung transplantation is of such an importance that a first person consent is considered necessary.

In our opinion, both arguments are only valid for patients suffering from chronic lung disease who require extracorporeal life support (ECLS) bridging -in ARDS they may not apply. Waking up an ARDS patient is often impossible, as unlike fibrosis patients who require ECLS bridging, ARDS patients are usually severely sick. 43 Their lung compliance is extremely poor with tidal volumes below 100mL. These unique challenges often result in severe stress and episodes of desaturation.

Our perspective is that given the severity of the disease and the lack of alternative therapies in transplant candidates a personal consent can be waived in many European countries. This requires the consent of a healthcare proxy or adult representative. However, in cases where the implementation of such a representative (designated by a court) takes too long the presumed will of the sedated patient has to be followed and a next-of-kin consent for J o u r n a l P r e -p r o o f transplantation is acceptable -under the assumption that the patient wants medically indicated treatment to save his/her life. When considering lung transplantation in ARDS patients, the 'right timing' is essential. Once the irreversibility of lung damage is confirmed, we recommend no attempts at weaning sedation to obtain personal consent. In critically ill patients, a longer ECLS time directly translates into higher complication rates, threating the success of a transplantation. 53 This 'window of opportunity' has to be considered when discussing the optimal time for listing an ARDS patient.

As published evidence is limited to a few case reports and only three small case series, no clear recommendation can be given about when and under what conditions to delist a deteriorating patient. Ideally, ARDS transplant candidates should be in a stable condition with a single-system organ failure. However, dysfunction of other organs is frequently seen. A temporary kidney failure in a patient with a previous normal kidney function is generally not considered a contraindication for lung transplantation in our centers. Therefore, patients who require kidney replacement therapy during their wait time should not be delisted. However, cholestatic liver dysfunction can pose a significant challenge. Secondary sclerosing cholangitis (SCC) is a dreadful complication in patients requiring prolonged ECLS for ARDS. 54, 55 As therapeutic options in patients who develop SSC are limited and mortality is extremely high, we consider rising cholestasis parameters a contraindication to lung transplantation in ARDS patients. The other two major contra-indications for ARDS lung transplantation are the development of uncontrolled diffuse bleeding during ECLS or a septic shock. However, if the reason for the septic shock is clearly the lung and the patient fails to stabilize, a bilateral pneumonectomy with a central Novalung/VA ECMO bridging concept can be considered. 56

Although the numbers of transplants for ARDS remains low compared to other indications, lung transplantation has become an established treatment for the subgroup of patients who do J o u r n a l P r e -p r o o f not recover. However, a sufficient time on ECLS has to be given in order to determine the regenerative potential of the native lung. Patient selection is crucial and transplantation should be reserved for those without a prospect of recovery. This usually limits the option of lung transplantation to those who were relatively healthy prior to the onset of ARDS. Good longterm results have been described after lung transplant in the carefully selected cohort of ARDS patients.

J o u r n a l P r e -p r o o f 

Fifty Years of Research in ARDS. The Epidemiology of Acute Respiratory Distress Syndrome. A 50th Birthday Review. American journal of respiratory and critical care medicine

Incidence and outcomes of acute lung injury

Acute Respiratory Distress Syndrome

Epidemiology of acute lung injury and acute respiratory distress syndrome

Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome

Mechanical Ventilation International Study, G., Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study

Clinical diagnostic criteria of the adult respiratory distress syndrome in the intensive care unit

Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries

Acute respiratory distress syndrome: the Berlin Definition

Validating Measures of Disease Severity in Acute Respiratory Distress Syndrome

Mortality rates for patients with acute lung injury/ARDS have decreased over time

The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance

Causes and characteristics of death in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome: a retrospective cohort study

Combined bronchoalveolar lavage and transbronchial lung biopsy: safety and yield in ventilated patients

The role of open-lung biopsy in ARDS

A contributive result of open-lung biopsy improves survival in acute respiratory distress syndrome patients

Four markers of collagen metabolism as possible indicators of disease in the adult respiratory distress syndrome

Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. American journal of respiratory and critical care medicine

Type III procollagen peptide in the adult respiratory distress syndrome. Association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death

Localization of insulinlike growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome. American journal of respiratory and critical care medicine

Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. American journal of respiratory and critical care medicine

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Lung transplantation for patients with severe COVID-19

Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis

Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosisassociated interstitial lung disease

Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis

Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis

Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis

Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis

Ineffectual Type 2-to-Type 1 Alveolar Epithelial Cell Differentiation in Idiopathic Pulmonary Fibrosis: Persistence of the KRT8(hi) Transitional State

Progressive Pulmonary Fibrosis Is Caused by Elevated Mechanical Tension on Alveolar Stem Cells

Query to reference single-cell integration with transfer learning

A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages

Circuit Design Features of a Stable Two-Cell System

Blood Institute Acute Respiratory Distress Syndrome Clinical Trials, N., Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome

Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease

A peptide derived from endostatin ameliorates organ fibrosis

Phospho-control of TGF-beta superfamily signaling

Comment on Let's Build Bridges to Recovery in COVID-19 ARDS

Lung Transplantation as a Therapeutic Option in Acute Respiratory Distress Syndrome

Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study

Lung transplantation for the treatment of irreversible acute respiratory distress syndrome

Lung transplantation for acute respiratory distress syndrome: A multicenter experience

Outcome after extracorporeal membrane oxygenation-bridged lung retransplants: a single-centre experience

Twenty-year experience with extracorporeal life support as bridge to lung transplantation

Extracorporeal life support as a bridge to lung transplantation-experience of a high-volume transplant center

Extracorporeal membrane oxygenation as a bridge to lung transplantation may not impact overall mortality risk after transplantation: results from a 7-year single-centre experience

Improving Outcomes in Bridge-to-Transplant: Extended Extracorporeal Membrane Oxygenation Support to Obtain Optimal Donor Lungs for Marginal Recipients

Mechanical ventilation and extracorporeal membrane oxygenation as a bridge to lung transplantation: Closing the gap

Outcomes of Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation

Awake Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation: A 9-Year Experience

Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation

Effects of the duration of bridge to lung transplantation with extracorporeal membrane oxygenation

Rare case of severe cholangiopathy following critical illness

Secondary sclerosing cholangitis following extracorporeal membrane oxygenation for acute respiratory distress in polytrauma

Bilateral pneumonectomy to treat uncontrolled sepsis in a patient awaiting lung transplantation